MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study.
MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study.
复制标题
DOI：
10.1016/j.bbmt.2016.11.021
复制
发表时间：
2017-03
期刊：
影响因子：
--
通讯作者：
Fernández-Viña M
中科院分区：
文献类型：
--
作者：
Askar M;Sobecks R;Wang T;Haagenson M;Majhail N;Madbouly A;Thomas D;Zhang A;Fleischhauer K;Hsu K;Verneris M;Lee SJ;Spellman SR;Fernández-Viña M
单中心研究先前报道了 MHC I 类链相关基因 A (MICA) 多态性和供体-受体 MICA 错配与无关供体造血细胞移植 (HCT) 后移植物抗宿主病 (GVHD) 的关联。在本研究中，我们研究了 HCT 后与 10/10 HLA 匹配 (n = 552) 或 9/10 (n = 161) 无关供体的 MICA 多态性（MICA-129、MM 与 MV 与 VV）和 MICA 错配之间的关联。其中包括 1999 年至 2011 年间向国际血液和骨髓移植研究中心报告的因急性淋巴细胞白血病、急性髓系白血病或骨髓增生异常综合征而首次接受不相关骨髓或外周血 HCT 的成年患者。我们的结果表明，MICA 错配和 MICA-129 多态性均与任何移植结果无关 (P < .01)，除了在移植中复发率较高之外。 MICA 不匹配的 HLA 10/10 供体受者（风险比 [HR]，1.7；P = .003）。有人建议 MICA 错配与 II 级至 IV 级急性 GVHD 较高风险之间存在关联（HR，1.4；P = .013）。MICA 错配与 HLA 匹配之间没有显着的相互作用（9/10 与 10/10）。总之，该队列的研究结果并未证实之前的研究报告，即 MICA 多态性和 MICA 错配与 HCT 结果相关。
Single-center studies have previously reported associations of MHC Class I Chain-Related Gene A (MICA) polymorphisms and donor-recipient MICA mismatching with graft-versus-host disease (GVHD) after unrelated donor hematopoietic cell transplantation (HCT). In this study, we investigated the association of MICA polymorphism (MICA-129, MM versus MV versus VV) and MICA mismatches after HCT with 10/10 HLA–matched (n = 552) or 9/10 (n = 161) unrelated donors. Included were adult patients with a first unrelated bone marrow or peripheral blood HCT for acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndrome that were reported to the Center for International Blood and Marrow Transplant Research between 1999 and 2011. Our results showed that neither MICA mismatch nor MICA-129 polymorphism were associated with any transplantation outcome (P < .01), with the exception of a higher relapse in recipients of MICA-mismatched HLA 10/10 donors (hazard ratio [HR], 1.7; P = .003). There was a suggestion of association between MICA mismatches and a higher risk of acute GVHD grades II to IV (HR, 1.4; P = .013) There were no significant interactions between MICA mismatches and HLA matching (9/10 versus 10/10). In conclusion, the findings in this cohort did not confirm prior studies reporting that MICA polymorphism and MICA mismatches were associated with HCT outcomes.